Blog - Page 232 of 5637 - QualityStocks

ThursdayAug 14, 2025 10:15 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN), a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and said it has sufficient cash runway into Q1 2026. The company plans to meet with the FDA this quarter to review survival data for lead candidate CNM-Au8 in amyotrophic lateral sclerosis (ALS) and is preparing analyses of NIH-sponsored Expanded Access Program neurofilament light biomarker data, expected in Q4. These steps are intended to support a potential New Drug Application submission under the FDA’s accelerated approval pathway for ALS by year-end 2025. Management said its focus remains on delivering an impactful therapy to the…

ThursdayAug 14, 2025 10:12 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials — LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma — along with completion of LP-184 Phase 1a enrollment, positioning it for Phase 1b/2 studies in high-value indications. LP-184 has FDA Fast Track and multiple Rare Pediatric Disease designations and showed significant survival gains in ATRT models. Lantern strengthened its IP with a European patent allowance for LP-284 and publication of…

ThursdayAug 14, 2025 9:25 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL is actively enrolling, with results anticipated in 2026. Soligenix also completed a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease, achieving its primary objective of demonstrating biological efficacy, and transferred manufacturing of synthetic hypericin to the U.S. under its Sterling…

ThursdayAug 14, 2025 9:00 am

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Advances New Craigmont Copper Project as AI Boom, Data-Center Surge Drives Copper Demand

The rise of AI has triggered an exponential growth in data-center construction and expansion, driving copper demand to unprecedented levels. Bell Canada has announced the construction of six new AI data centers in British Columbia, including one in Merritt, British Columbia, strategically located near Nicola Mining. The company recently provided updates on Craigmont exploration results, including drilling 14 holes with early findings revealing copper sulphide mineralization. Copper's superior conductivity makes it a critical metal in the artificial intelligence (“AI”) era, serving as the backbone of data-center infrastructure. Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is positioning itself to meet escalating industrial…

ThursdayAug 14, 2025 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic agreement with standard 12-lead ECGs. HeartBeam is executing commercial readiness plans, including establishing manufacturing, logistics, and cardiologist review services, with launch expected after clearance. Additional highlights include an accepted AI algorithm abstract for HRX Live 2025, issuance of a new international patent bringing the total…

WednesdayAug 13, 2025 11:36 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, will present at the Emerging Growth Conference on Aug. 20, 2025, at 2:20 p.m. ET. The virtual session will feature a corporate update followed by a Q&A, with a live webcast available through the Events section of Clene’s website and via the conference registration link and replays accessible through the conference portal and YouTube channel. To view the full press release, visit https://ibn.fm/zfWSL About Clene Inc. Clene Inc., (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is…

WednesdayAug 13, 2025 10:55 am

Scalability of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Tailings Model Represents Profitable Mining Approach Throughout The Americas

Sustainable mining company ESGold is stretching beyond its nascent Quebec mine tailings cleanup operation to evaluate its scalability for potential revenue generation at any of the thousands of similar sites throughout the Americas The company is nearing the finish line in facilities construction for tailings recovery at an abandoned legacy operation west of Quebec’s capital city, where it expects to generate up to $350 million during the coming decade from the tailings cleanup and near-surface hard rock ESGold expects to recover residual gold and silver from the tailings, while processing other mineralization for a concentrate The near-term tailings reprocessing strategy…

WednesdayAug 13, 2025 10:53 am

QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Acquires Go Fast Sports Brand in Move Into Functional Beverage Market

Golden Triangle Ventures (OTC: GTVH) (“GTV”) reached an agreement with Labor Smart, Inc. (OTC: LTNC) to acquire the Go Fast Sports brand, including all assets, trademarks, inventory and related rights, marking its first major acquisition under incoming CEO Javier Leal. The deal was completed without issuing GTVH stock or convertible notes, as Leal contributed 720 million of his personal LTNC shares to the transaction, calling it a gift to shareholders. Founded in 1996, Go Fast Sports is a lifestyle-driven energy brand with a global following in extreme sports, motorsports and athletic communities, and will anchor GTVH’s Beverages & Health division alongside…

WednesdayAug 13, 2025 9:23 am

QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Announces Juve Stabia Coppa Italia Opener Against Serie A’s US Lecce

Brera Holdings (NASDAQ: BREA), an Ireland-based multi-club football ownership company, announced that its majority-owned Serie B club S.S. Juve Stabia will face Serie A squad US Lecce in an away match on Aug. 15, 2025, in the Coppa Italia round of 32 at the 32,000-seat Via Del Mare Stadium. Known as “The Other Team of Naples,” Juve Stabia earned the fixture after a strong 2024-25 season, finishing fifth in Serie B and reaching the Serie A promotion playoffs semifinals. The club also recorded the highest market value increase in Serie B last season, up 245% to $32 million from $9.3…

WednesdayAug 13, 2025 9:00 am

QualityStocksNewsBreaks – FAVO Capital (OTC: FAVO) Acquires $190 Million Mixed-Use Property 1818 Park in All-Stock Deal

FAVO Capital (OTC: FAVO), a diversified finance company providing alternative revenue-based funding to SMBs, completed its $190 million all-stock and assumption-of-liabilities acquisition of 1818 Park, a Class-A mixed-use property in downtown Hollywood, Florida. The newly built, high-occupancy asset features residential, office, and retail space with long-term leases, delivering stable cash flow and expanding FAVO’s portfolio into income-generating real estate. Former owners led by GCF Development will become long-term equity partners, ensuring operational continuity. Management said the acquisition strengthens FAVO’s balance sheet, broadens its collateral base, supports larger financing lines, and enhances private credit growth while aligning with the company’s long-term, diversified…

Site Search

Company Search